Status:
TERMINATED
Generation of Cancer Antigen-Specific T-cells From Human Induced Pluripotent Stem Cells (iPSC) for Research and Potential FutureTherapy
Lead Sponsor:
National Cancer Institute (NCI)
Conditions:
Gastrointestinal Cancers
Breast Cancer
Eligibility:
All Genders
15+ years
Brief Summary
Background: Researchers want to test if certain cells can be re-programmed into stem cells. Stem cells can keep reproducing for a long time. Cells made by stem cells can be turned into different type...
Detailed Description
Background: T-cells are potentially curative for patients with metastatic cancer, but many patients with cancer have T-cells that are terminally differentiated , a condition associated with treatment...
Eligibility Criteria
Inclusion
- INCLUSION CRITERIA:
- Patients with a cancer diagnosis enrolled on protocol 03-C-0277.
- Willing and able to provide informed consent
- Patients must be greater than or equal to 15 years of age.
- EXCLUSION CRITERIA:
- Healthy donors enrolled on protocol 03-C-0277.
Exclusion
Key Trial Info
Start Date :
January 30 2018
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
September 30 2019
Estimated Enrollment :
98 Patients enrolled
Trial Details
Trial ID
NCT03407040
Start Date
January 30 2018
End Date
September 30 2019
Last Update
November 10 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
National Institutes of Health Clinical Center
Bethesda, Maryland, United States, 20892